Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159730 | 1.00 | MAPT (0.47) | MAPTHTTCNR2GAATP53 | |
| SCHEMBL4153584 | 0.91 | SPPL2A (0.40) | MAPTHTTSPPL2ALMNAMEN1 | |
| SCHEMBL4153589 | 0.91 | SPPL2A (0.40) | MAPTHTTSPPL2ALMNAMEN1 | |
| SCHEMBL4159035 | 0.90 | SPPL2A (0.44) | SPPL2ALMNAMLNRABCB11CTSD | |
| SCHEMBL4159037 | 0.90 | SPPL2A (0.44) | SPPL2ALMNAMLNRABCB11CTSD | |
| SCHEMBL1602740 | 0.88 | SPPL2A (0.42) | SPPL2A | |
| SCHEMBL1602741 | 0.88 | SPPL2A (0.42) | SPPL2A | |
| SCHEMBL4157709 | 0.88 | SPPL2A (0.40) | MAPTTP53SPPL2ALMNAMLNR | |
| SCHEMBL4157713 | 0.88 | SPPL2A (0.40) | MAPTTP53SPPL2ALMNAMLNR | |
| SCHEMBL4157649 | 0.86 | ADAMTS4 (0.46) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1637518-A2 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1159278-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040127488-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-01 | — | — | US | disclosed |
| US-6617350-B2 | Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-09 | — | — | US | disclosed |
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
| EP-1159278-A2 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6319946-B1 | BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| WO-2000047551-A2 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MAPT 1868/4885HTT 1847/4885CNR2 4548/4885 |
| US-20040127488-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MAPT 1868/4885HTT 1847/4885CNR2 4548/4885 |
| US-20020198388-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MAPT 1868/4885HTT 1847/4885CNR2 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.